Answers are grounded in this paper and cite their sources.
To the Editor. —Betaxolo hydrochloride, a β1adrenergic receptor blocking agent, has a low incidence of systemic effects and has been shown to be clinically safe and effective for the treatment of glaucoma.1However, a recent case report has documented respiratory problems with the use of topical betaxolo.2We wish to report a case of reduction in pulmonary capacity following the use of topical betaxolol, as well as the failure of systemic therapy to alleviate symptoms, in a patient with minimal reactive airway disease. Report of a Case. —A 71-year-old woman had pseudoexfoliative glaucoma of the right eye. Ocular tensions in this eye ranged from 25 to 30 mm Hg. The optic disc had a cup-to-disc ratio of 0.9. A superior paracentral scotoma was present in the right eye. The left eye had a normal intraocular pressure, cup-to-disc ratio, and visual field. She was allergic to pilocarpine
No takes yet. Share an insight, caveat, or question.
Philip C. Roholt (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: